IZ
IZOZF.US Izotropic Corporation
- Market cap
- USD 6.22M
- P/E
- -
- P/B
- 115.81x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is IZOZF.US undervalued?
Graham numberThe Graham number of Izotropic Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Izotropic Corporation fundamental analysis
No fundamental analysis for Izotropic Corporation yet.
Izotropic Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Izotropic Corporation
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a breast CT imaging system. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Full company profileIzotropic Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Izotropic Corporation annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -33.9K | - | - | - | - | - | - | - | - | - |
| Operating Income | -72.7K | -705K | -399K | -1.16M | -4.98M | -6.64M | -5.33M | -1.70M | -2.22M | -1.44M | -1.40M |
| EBITDA | -74.3K | -701K | -392K | -1.15M | -4.97M | -6.63M | -5.34M | -1.25M | -2.80M | -1.67M | -1.82M |
| Net Income | -98.3K | -730K | -399K | -1.16M | -4.98M | -6.65M | -5.66M | -1.56M | -3.14M | -2.18M | -2.11M |
| EPS | 0.00 | -0.03 | -0.02 | -0.04 | -0.12 | -0.15 | -0.11 | -0.03 | -0.05 | -0.03 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 150K | 492K | 339K | 777K | 4.69M | 2.27M | 442K | 232K | 415K | 440K | 269K |
| Total Liabilities | 214K | 83.9K | 22.2K | 70.0K | 169K | 2.64M | 3.52M | 4.08M | 5.27M | 6.06M | 6.42M |
| Shareholders' Equity | -64.7K | 408K | 317K | 707K | 4.52M | -375K | -3.07M | -3.85M | -4.86M | -5.63M | -6.16M |
| Cash & Short-term Investments | 149K | 472K | 309K | 614K | 4.06M | 1.86M | 166K | 38.6K | 274K | 220K | 57.8K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -55.2K | -605K | -443K | -987K | -3.08M | -4.76M | -3.27M | -594K | -636K | -851K | -406K |
| Capital Expenditure | 17.6K | 17.6K | 24.2K | 24.2K | 24.2K | 24.2K | 36.2K | 0.00 | 1.14K | 0.00 | 0.00 |
| Free Cash Flow | -50.6K | -622K | -443K | -987K | -3.08M | -4.79M | -3.30M | -594K | -637K | -851K | -406K |
| Ratios | |||||||||||
| ROE | - | -179.1% | -125.8% | -163.4% | -110.2% | - | - | - | - | - | - |
| ROA | -65.7% | -148.5% | -117.5% | -148.7% | -106.2% | -293.3% | -1,280.5% | -671.9% | -757.1% | -496.8% | -783.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Izotropic Corporation dividends
Izotropic Corporation has not paid dividends in the last 9 fiscal years.
Who owns Izotropic Corporation
- Insiders 7.67%
- Institutions 0.00%
- Public & others 92.33%
- Shares outstanding 72.3M
- Free float 66.0M
Izotropic Corporation company profile
- Company name
- Izotropic Corporation
- Ticker
- IZOZF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- April
- Address
- 800-15355 24th Avenue, Surrey, BC, Canada, V4A 2H9
- Phone
- 833-496-2677
- Website
- izocorp.com
About Izotropic Corporation
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a breast CT imaging system. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Izotropic Corporation management
6- Mr. Robert Louis ThastFounder, Interim CEO & Chairman · born 1954
- Mr. Ralph F. Proceviat CPACFO & Director · born 1950
- Dr. Younes Achkire Ph.D.Executive VP of Product Engineering & COO
- Mr. Ali Reza SodagarLegal Advisor & Independent Director
- Dr. Andrew M. HernandezHead of Imaging Technology
- Ms. Jaclyn ThastOperations Manager & Corporate Secretary